Systemic Erythropoietin Injection in Patients Having Optic Atrophy

Phase 1

Completed

• Conditions: Optic Atrophy
• Interventions: Drug: Systemic erythropoietin injection

• Registration Number: NCT04680143
• Lead Sponsor: Alexandria University

Brief Summary

The purpose of this treatment trial is to study the effect of systemic erythropoietin in patients having optic atrophy.

Detailed Description

The purpose of this treatment trial is to study the effect of systemic erythropoietin in patients having optic atrophy. The intervention is systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).

Follow up after one month and three months by recording visual acuity and electro physiological studies.

Study Timeline

• Study Start: 2020-09-01
• Study First Submitted: 2020-12-15
• Study First Submitted QC: 2020-12-19
• Study First Posted: 2020-12-22
• Primary Completion: 2021-03-01
• Study Completion: 2021-03-30
• Status Verified: 2021-07
• Last Update Submitted: 2021-07-11
• Last Update Posted: 2021-07-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Post papilledemic optic atrophy patients

Exclusion Criteria

• Refuse to give an informed consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Systemic erythropoietin injections	Systemic erythropoietin injection	The study included 10 patients diagnosed as post papilledemic optic atrophy

Primary Outcome Measures

Name	Time	Method
Visual acuity	3 months	VIsual acuity assessed at the follow up
Pattern visual evoked Potential .	3 months	Pattern visual evoked Potential .in both eyes to use data of the normal fellow eye as patients' internal control
Pattern electroretinogram	3 months	Pattern electroretinogram in both eyes to use data of the normal fellow eye as patients' internal control

Trial Locations

Locations (1)

Alexandria Faculty of Medicine; 🇪🇬 Alexandria, Egypt